Biased NMDA Receptor Modulators for Tri-Heteromer Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing therapies targeting NMDA receptor subtypes are biased towards di-heteromeric receptors, neglecting the role of tri-heteromeric receptors in neurological and psychiatric diseases, leading to challenges in developing effective modulators for these subtypes.
Innovation Solution
Development of compounds that selectively modulate tri-heteromeric NMDA receptors, particularly GluN1/2A/2B, as biased allosteric modulators, which can be administered alone or in pharmaceutical formulations with auxiliary agents to treat NMDA receptor-mediated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds are designed to target di-heteromeric NMDA receptors (GluN1/2A and GluN1/2B), then existing therapeutic options are available, but selectivity for tri-heteromeric NMDA receptors (GluN1/2A/2B) is not achieved
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular features that selectively interact with tri-heteromeric NMDA receptors. The compounds contain particular structural elements (such as substituted piperidine rings, specific functional groups at defined positions) that create localized interactions with the GluN1/2A/2B receptor subtype, enabling selective modulation without affecting other NMDA receptor subtypes.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters of the compounds (substituent types, positions, and configurations) to optimize selectivity for tri-heteromeric receptors. By adjusting chemical parameters such as the nature of R groups, ring substitutions, and molecular geometry, the compounds achieve enhanced specificity for GluN1/2A/2B while maintaining desired pharmacological activity.
2Reliability
If NMDA receptor activity is increased to treat hypofunction, then synaptic plasticity may be improved, but excitotoxicity and neuron death may occur
Solution Approach 1:
The patent applies local quality by targeting specific NMDA receptor subtypes (tri-heteromeric GluN1/2A/2B) rather than all NMDA receptors uniformly. This selective approach allows modulation of receptor activity in specific neural circuits or contexts where hypofunction is problematic, while avoiding overactivation in regions where excitotoxicity is a concern, thus achieving therapeutic efficacy with reduced harmful effects.
Solution Approach 2:
The patent employs partial action by using compounds that provide moderate potentiation of tri-heteromeric NMDA receptors rather than maximal activation. The compounds achieve sufficient enhancement of synaptic plasticity and neuronal function to treat hypofunction, while maintaining activity levels below the threshold that triggers excitotoxicity and neuronal damage.
3Loss of information
If research focuses on canonical di-heteromeric NMDA receptor subtypes, then established knowledge is leveraged, but the role of tri-heteromeric subtypes in disease remains unexplored
Solution Approach 1:
The patent applies preliminary action by providing a head start in the exploration of tri-heteromeric NMDA receptors through the disclosure of selective compounds and their characterization. This preliminary work establishes a foundation for future research and drug development, reducing the time required for other researchers to discover and validate the therapeutic potential of tri-heteromeric receptor targeting.
Solution Approach 2:
The patent uses the selectively designed compounds as intermediaries to bridge the gap between established knowledge of di-heteromeric receptors and the unexplored territory of tri-heteromeric receptors. These compounds serve as tool molecules that enable researchers to study and understand the specific role of GluN1/2A/2B receptors in neurological and psychiatric diseases, accelerating the overall pace of discovery.
Data Source
AI summary
Described herein are compounds that can be capable of modulating an N-methyl-D-aspartate (NMDA) receptor. In some embodiments, the compound(s) can be a biased modulator of an NMDA receptor. In some embodiments, the compound(s) can be a biased allosteric modulator of an NMDA receptor. Also described herein are methods of treating an NMDA-mediated disease by administering one or more of the compounds described herein. In some embodiments, the compounds can be effective to treat a neurobiological or psychiatric disease or disorder.